100 related articles for article (PubMed ID: 10689713)
1. Clinical ineffectiveness of IL-2 and/or IFN alpha administration after autologous PBSC transplantation in pediatric oncological patients.
Vlk V; Eckschlager T; Kavan P; Kabícková E; Koutecký J; Sobota V; Bubenik J; Pospísilová D
Pediatr Hematol Oncol; 2000; 17(1):31-44. PubMed ID: 10689713
[TBL] [Abstract][Full Text] [Related]
2. Immunologic effects of intermediate-dose IL-2 i.v. after autologous hematopoietic cell transplantation in pediatric solid tumors.
Kalwak K; Ussowicz M; Gorczyńska E; Turkiewicz D; Toporski J; Dobaczewski G; Latos-Grazyńska E; Ryczan R; Noworolska-Sauren D; Chybicka A
J Interferon Cytokine Res; 2003 Apr; 23(4):173-81. PubMed ID: 12856329
[TBL] [Abstract][Full Text] [Related]
3. Ex vivo cytokine activation of peripheral blood stem cells: a potential role for adoptive cellular immunotherapy.
Meehan KR; Wu A; Hassan R; Miao Y; Chawla J; Slack R; Gehan E; Herscowitz HB
J Hematother Stem Cell Res; 2001 Apr; 10(2):283-90. PubMed ID: 11359675
[TBL] [Abstract][Full Text] [Related]
4. Progression of natural immunity during one-year treatment of residual disease in neuroblastoma patients with high doses of interleukin-2 after autologous bone marrow transplantation.
Martí F; Pardo N; Peiró M; Bertran E; Amill B; García J; Cubells J; Rueda F
Exp Hematol; 1995 Dec; 23(14):1445-52. PubMed ID: 8542930
[TBL] [Abstract][Full Text] [Related]
5. [Preliminary assessment of immune reconstitution after autologous peripheral hematopoietic stem cell transplantation (AHSCT)].
Huang HQ; Cai QC; Shi YX; Lin XB; Wei J; Guo Y; Pan ZH
Ai Zheng; 2006 Aug; 25(8):1023-8. PubMed ID: 16965687
[TBL] [Abstract][Full Text] [Related]
6. Effect of blood transfusion during radiotherapy on the immune function of patients with cancer of the uterine cervix: role of interleukin-10.
Santin AD; Bellone S; Palmieri M; Bossini B; Dunn D; Roman JJ; Pecorelli S; Cannon M; Parham GP
Int J Radiat Oncol Biol Phys; 2002 Dec; 54(5):1345-55. PubMed ID: 12459356
[TBL] [Abstract][Full Text] [Related]
7. Transplenic and transtumoral in vivo immunostimulation: effect on cellular immunity parameters.
Boura P; Kountouras J; Lygidakis NJ; Safioleas M; Aphinives P
Hepatogastroenterology; 1999; 46(26):799-803. PubMed ID: 10370616
[TBL] [Abstract][Full Text] [Related]
8. CD69, CD25, and HLA-DR activation antigen expression on CD3+ lymphocytes and relationship to serum TNF-alpha, IFN-gamma, and sIL-2R levels in aging.
Rea IM; McNerlan SE; Alexander HD
Exp Gerontol; 1999 Jan; 34(1):79-93. PubMed ID: 10197730
[TBL] [Abstract][Full Text] [Related]
9. Immunomodulation of early engrafted natural killer cells with interleukin-2 and interferon-alpha in autologous stem cell transplantation.
Porrata LF; Inwards DJ; Lacy MQ; Markovic SN
Bone Marrow Transplant; 2001 Oct; 28(7):673-80. PubMed ID: 11704790
[TBL] [Abstract][Full Text] [Related]
10. Stimulation of T-cell cytokine production and NK-cell function by IL-2, IFN-alpha and histamine treatment during remission of non-Hodgkin's lymphoma.
Ahlberg R; MacNamara B; Andersson M; Zheng C; Svensson A; Holm G; Hansson M; Porwit-MacDonald A; Björkholm M; Sundblad A
Hematol J; 2003; 4(5):336-41. PubMed ID: 14502258
[TBL] [Abstract][Full Text] [Related]
11. The role of tumor cells in the modification of T lymphocytes activity--the expression of the early CD69+, CD71+ and the late CD25+, CD26+, HLA/DR+ activation markers on T CD4+ and CD8+ cells in squamous cell laryngeal carcinoma. Part I.
Starska K; Głowacka E; Kulig A; Lewy-Trenda I; Bryś M; Lewkowicz P
Folia Histochem Cytobiol; 2011; 49(4):579-92. PubMed ID: 22252752
[TBL] [Abstract][Full Text] [Related]
12. Independent expression of p55 and p75 interleukin-2 receptors (IL-2R) during intravenous or subcutaneous administration of recombinant interleukin-2 (rIL-2) by T-lymphocytes and natural killer cells.
Zambello R; Trentin L; Cerutti A; Enthammer C; Milani A; Franceschi T; Messina C; Cetto GL; Agostini C; Semenzato G
Cancer; 1994 Nov; 74(9):2562-9. PubMed ID: 7522954
[TBL] [Abstract][Full Text] [Related]
13. Induction of autocytotoxic T cells with cyclosporine and interferon-gamma for patients with non-Hodgkin's lymphoma after transplantation of peripheral blood stem cells.
Nakao S; Miura Y; Zeng W; Takami A; Sugimori N; Yamazaki H; Yachie A; Shiobara S; Matsuda T
J Allergy Clin Immunol; 1997 Dec; 100(6 Pt 2):S65-9. PubMed ID: 9440547
[TBL] [Abstract][Full Text] [Related]
14. Lymphocyte recovery and clinical response in multiple myeloma patients receiving interferon alpha 2 beta after intensive therapy.
Millar BC; Bell JB; Powles RL
Br J Cancer; 1996 Jan; 73(2):236-40. PubMed ID: 8546912
[TBL] [Abstract][Full Text] [Related]
15. Effects of concurrent cisplatinum administration during radiotherapy vs. radiotherapy alone on the immune function of patients with cancer of the uterine cervix.
Santin AD; Hermonat PL; Ravaggi A; Bellone S; Roman J; Pecorelli S; Cannon M; Parham GP
Int J Radiat Oncol Biol Phys; 2000 Nov; 48(4):997-1006. PubMed ID: 11072156
[TBL] [Abstract][Full Text] [Related]
16. Low-dose natural interleukin-2 and recombinant interferon-gamma following autologous bone marrow grafts in pediatric patients with high-risk acute leukemia.
Baumgarten E; Schmid H; Pohl U; Brzoska J; Linderkamp C; Siegert W; Henze G
Leukemia; 1994 May; 8(5):850-5. PubMed ID: 8182941
[TBL] [Abstract][Full Text] [Related]
17. A randomized phase II trial comparing two different sequence combinations of autologous vaccine and human recombinant interferon gamma and human recombinant interferon alpha2B therapy in patients with metastatic renal cell carcinoma: clinical outcome and analysis of immunological parameters.
Schwaab T; Heaney JA; Schned AR; Harris RD; Cole BF; Noelle RJ; Phillips DM; Stempkowski L; Ernstoff MS
J Urol; 2000 Apr; 163(4):1322-7. PubMed ID: 10737537
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy with concurrent subcutaneous GM-CSF, low-dose IL-2 and IFN-alpha in patients with progressive metastatic renal cell carcinoma.
Verra N; Jansen R; Groenewegen G; Mallo H; Kersten MJ; Bex A; Vyth-Dreese FA; Sein J; van de Kasteele W; Nooijen WJ; de Waal M; Horenblas S; de Gast GC
Br J Cancer; 2003 May; 88(9):1346-51. PubMed ID: 12778059
[TBL] [Abstract][Full Text] [Related]
19. Activation of the immune system of cancer patients by continuous i.v. recombinant IL-2 (rIL-2) therapy is dependent on dose and schedule of rIL-2.
Gratama JW; Bruin RJ; Lamers CH; Oosterom R; Braakman E; Stoter G; Bolhuis RL
Clin Exp Immunol; 1993 May; 92(2):185-93. PubMed ID: 8485906
[TBL] [Abstract][Full Text] [Related]
20. Time course of interferon-gamma production deficiency after autologous and allogeneic stem cell transplantation for malignancies.
Hanenberg H; Dilloo D; Laws HJ; Zessack N; Heyll A; Burdach S
Exp Hematol; 1995 Dec; 23(14):1543-52. PubMed ID: 8542945
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]